Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study

被引：0

作者：

Dietrich, Sascha ^{[1
]}

Tilly, Herve ^{[2
,3
]}

Morschhauser, Franck ^{[4
]}

Sehn, Laurie H. ^{[5
,6
]}

Friedberg, Jonathan W. ^{[7
]}

Trneny, Marek ^{[8
]}

Sharman, Jeff ^{[9
]}

Herbaux, Charles ^{[10
]}

Burke, John M. ^{[11
]}

Matasar, Matthew ^{[12
]}

Rai, Shinya ^{[13
]}

Izutsu, Koji ^{[14
]}

Mehta-Shah, Neha ^{[15
]}

Oberic, Lucie ^{[16
]}

Chauchet, Adrien ^{[17
]}

Jurczak, Wojciech ^{[18
]}

Song, Yu Qin ^{[19
]}

Greil, Richard ^{[20
,21
]}

Mykhalska, Larysa ^{[22
]}

Bergua Burgues, Juan Miguel ^{[23
]}

Cheung, Matthew C. ^{[24
]}

Pinto, Antonio ^{[25
]}

Shin, Ho-Jin ^{[26
]}

Hapgood, Greg ^{[27
]}

Munhoz, Eduardo ^{[28
]}

Salles, Gilles ^{[12
]}

机构：

[1] Univ Klinikum Heideberg, Klin Hamatol Onkol Rheumatol, Heidelberg, Germany

[2] Ctr Henri Becquerel, Rouen, France

[3] Univ Rouen, Rouen, France

[4] Univ Lille, Grp Rech Formes Injectables & Technol Associees, CHU Lille, Lille, France

[5] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[6] Univ British Columbia, Vancouver, BC, Canada

[7] UR Med Wilmot Canc Ctr, Rochester, NY USA

[8] Charles Univ Prague, Gen Hosp, Fac Med 1, Prague, Czech Republic

[9] US Oncol, Willamette Valley Canc Inst, Eugene, OR USA

[10] CHU Montpellier, Montpellier, France

[11] US Oncol, Rocky Mt Canc Ctr, Aurora, CO USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY USA

[13] Kindai Univ, Fac Med, Osaka Sayama City, Japan

[14] Natl Canc Ctr, Tokyo, Japan

[15] Washington Univ, St Louis, MO USA

[16] Toulouse Oncopole, Inst Univ Canc, Toulouse, France

[17] CHRU Besancon, Dept Hematol, Besancon, France

[18] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[19] Peking Univ Canc Hosp, Beijing, Peoples R China

[20] Paracelsus Med Univ, Salzburg Canc Res Inst CCCIT, Salzburg, Austria

[21] Canc Cluster Salzburg, Salzburg, Austria

[22] Clin Hosp Feofaniya, Kiev, Ukraine

[23] Hosp San Pedro Alcantara, Caceres, Spain

[24] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[25] IRCCS, Hematol Oncol Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy

[26] Pusan Natl Univ, Sch Med, Med Res Inst, Pusan Natl Univ Hosp, Busan, South Korea

[27] Princess Alexandra Hosp, Brisbane, Qld, Australia

[28] Hosp Erasto Gaertner, Curitiba, Parana, Brazil

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

891

引用

页码：165 / 165

页数：1

共 50 条

[41] Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study
Zhao, Peiqi
Zhao, Shu
Huang, Chen
Li, Yajun
Wang, Jiesong
Xu, Junqing
Li, Lanfang
Qian, Zhengzi
Li, Wei
Zhou, Shiyong
Qiu, Lihua
Liu, Xianming
Chen, Ying
Jiang, Yanan
Zheng, Yanbin
Chen, Daoguang
Zhou, Hui
Gao, Yuhuan
Zhang, Qingyuan
Zhang, Huilai
HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
[42] Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Offner, Fritz
Samoilova, Olga
Osmanov, Evgenii
Eom, Hyeon-Seok
Topp, Max S.
Raposo, Joao
Pavlov, Viacheslav
Ricci, Deborah
Chaturvedi, Shalini
Zhu, Eugene
van de Velde, Helgi
Enny, Christopher
Rizo, Aleksandra
Ferhanoglu, Burhan
BLOOD, 2015, 126 (16) : 1893 - 1901
[43] A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma
Fowler, Nathan Hale
Hiddemann, Wolfgang
Leonard, John
Rose, Esther
Ahmadl, Tahamtan
Vermeulen, Jessica
Larsen, Julie S.
Sun, Steven
Mentzer, Lisa
Wang, Shean-Shang
Yeh, Tzu-Min
Sallee, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[44] OUTCOMES IN PATIENTS WITH PRIMARY GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA AFTER RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) CHEMOTHERAPY
Suh, C.
Sohn, B. S.
Yoon, D. H.
Kim, S.
Lee, D. H.
Kim, S. W.
Huh, J. R.
Lee, J. S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 650 - 650
[45] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy
Sohn, B.
Yoon, D.
Kim, S.
Lee, D.
Kim, S.
Huh, J.
Lee, J.
Suh, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[46] A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).
Tilly, Herve
Flowers, Christopher
Friedberg, Jonathan W.
Herbaux, Charles
Morschhauser, Franck
Sehn, Laurie Helen
Sharman, Jeff Porter
Trneny, Marek
Wang, Lijia
Lee, Calvin
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
Camus, Vincent
Thieblemont, Catherine
Gaulard, Philippe
Cheminant, Morgane
Casasnovas, Rene-Olivier
Ysebaert, Loic
Damaj, Gandhi Laurent
Guidez, Stephanie
Pica, Gian Matteo
Kim, Won Seog
Lim, Soon Thye
Andre, Marc
Gutierrez, Norma
Penarrubia, Maria Jesus
Staber, Philipp B.
Trotman, Judith
Huettmann, Andreas
Stefoni, Vittorio
Tucci, Alessandra
Fogarty, Patrick
Farhat, Hassan
Abraham, Julie
Abarah, Wajed
Belmecheri, Fatiha
Ribrag, Vincent
Delfau-Larue, Marie-Helene
Cottereau, Anne-Segolene
Itti, Emmanuel
Li, Ju
Delarue, Richard
de Leval, Laurence
Morschhauser, Franck
Bachy, Emmanuel
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (14) : 1612 - 1618
[48] Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubucin and Rituximab (da-EPOCH-R) Vs Rituxan, Cyclophosphamide, Doxorubucin, Vincristine and Prednisone (R-CHOP) As First Line Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)
Padhi, Parikshit
Chilkulwar, Abhishek
Khan, Cyrus
Patel, Monank
Lister, John
Tang, Xiaoqin
BLOOD, 2016, 128 (22)
[49] Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma
Arima, Hiroshi
Maruoka, Hayato
Nasu, Koji
Tabata, Sumie
Kurata, Masayuki
Matsushita, Akiko
Imai, Yukihiro
Takahashi, Takayuki
Ishikawa, Takayuki
LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2645 - 2653
[50] Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma
Gao, Yuhuan
Xie, Yan
Liu, Lihong
Xue, Hongwei
Hou, Ming
Zhang, Mingzhi
Zhou, Zeping
Guo, Pengxiang
Yao, Hongxia
Shao, Zonghong
Xie, Xiaobao
Zhu, Jun
MINERVA MEDICA, 2021, 112 (02) : 310 - 312

← 1 2 3 4 5 →